NCT03663725 2026-03-18
StrateGlio
Centre Oscar Lambret
Phase 3 Recruiting
Clinical Trials
651 trialsNCT04655404 2026-03-18
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
Nationwide Children's Hospital
Phase EARLY_PHASE1 Recruiting
NCT04678648 2026-03-18
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics, Inc.
Phase 1 Recruiting
NCT05099003 2026-03-18
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT05500391 2026-03-18
SUR-CAN
Centre Oscar Lambret
Phase 2 Recruiting
NCT05859334 2026-03-18
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06325683 2026-03-18
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06860594 2026-03-18
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT07480941 2026-03-18
DUAL-CAR-NK-GB
Beijing Biotech
Phase 1 Recruiting
NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
NCT04732065 2026-03-17
PNOC023
University of California, San Francisco
Phase 1 Recruiting
NCT05170815 2026-03-17
ErYs
Clariance
Recruiting
NCT06161519 2026-03-17
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06344130 2026-03-17
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06926075 2026-03-17
ADVICE
Filamon LTD
Phase 1/2 Recruiting
NCT06934889 2026-03-17
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07476794 2026-03-17
TEMPO
Sunnybrook Health Sciences Centre
Phase 2 Recruiting
NCT04485559 2026-03-16
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
University of California, San Francisco
Phase 1 Recruiting
NCT05057702 2026-03-16
PNOC027
University of California, San Francisco
Phase NA Recruiting
NCT06186401 2026-03-16
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
University of California, San Francisco
Phase 1 Recruiting
NCT00107289 2026-03-13
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT01804634 2026-03-13
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT02390752 2026-03-13
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT04936529 2026-03-13
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05588141 2026-03-13
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05940493 2026-03-13
Abemaciclib in Newly Diagnosed Meningioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase 2 Recruiting
NCT06556563 2026-03-13
EF-41
NovoCure Ltd.
Phase 3 Recruiting
NCT02287428 2026-03-12
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT02896335 2026-03-12
Palbociclib and Pembrolizumab In Central Nervous System Metastases
Massachusetts General Hospital
Phase 2 Recruiting
NCT05417594 2026-03-12
CERTIS1
AstraZeneca
Phase 1/2 Recruiting
NCT06188741 2026-03-12
NF114
University of Alabama at Birmingham
Phase 2 Recruiting
NCT06333899 2026-03-12
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Nationwide Children's Hospital
Phase EARLY_PHASE1 Recruiting
NCT07100730 2026-03-12
IPAX BrIGHT
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT07297212 2026-03-12
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
Phase 2 Recruiting
NCT07464470 2026-03-12
GENCONCOR-2
Blokhin's Russian Cancer Research Center
Recruiting
NCT00598351 2026-03-11
Natural History Study of Patients With Neurofibromatosis Type 2
National Institutes of Health Clinical Center (CC)
Recruiting
NCT01109394 2026-03-11
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
National Institutes of Health Clinical Center (CC)
Recruiting
NCT02639325 2026-03-11
Tumor Related Epilepsy
National Institutes of Health Clinical Center (CC)
Recruiting
NCT05086497 2026-03-11
WBSI Guided Personalized Delivery of TTFields
Abramson Cancer Center at Penn Medicine
Phase NA Recruiting
NCT06395103 2026-03-11
MK-9999-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06504381 2026-03-11
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
University of California, San Francisco
Phase 1/2 Recruiting
NCT06625190 2026-03-11
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
University of Florida
Phase 1/2 Recruiting
NCT06914479 2026-03-11
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
University of Michigan Rogel Cancer Center
Phase 1 Recruiting
NCT04752280 2026-03-10
GRIPS
University Hospital Heidelberg
Phase NA Recruiting
NCT05378633 2026-03-10
CyberChallenge
University Hospital Heidelberg
Phase NA Recruiting
NCT05503797 2026-03-10
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Fore Biotherapeutics
Phase 2 Recruiting
NCT06104930 2026-03-10
MOLI
University Hospital Heidelberg
Phase NA Recruiting
NCT06427798 2026-03-10
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT07063693 2026-03-10
ABY-029 Glioma Trial
Dartmouth-Hitchcock Medical Center
Phase 1 Recruiting
NCT05465174 2026-03-09
PNOC029
University of California, San Francisco
Phase 2 Recruiting